Autoimmune polyendocrine syndrome screening: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) |
||
| Line 6: | Line 6: | ||
==Screening== | ==Screening== | ||
Screening is an important aspect in early diagnosis and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single endocrine disorder and the subsequent involvement of other endocrine/non-endocrine organs may take up to years or decades. In patients of APS, high clinical suspicion should be maintained for presence of other autoimmune disorders. | [[Screening]] is an important aspect in early [[diagnosis]] and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single [[endocrine disorder]] and the subsequent involvement of other [[endocrine]]/non-endocrine [[organs]] may take up to years or decades. In patients of APS, high [[clinical]] suspicion should be maintained for presence of other autoimmune disorders. | ||
* In APS type 1, the time interval between onset of mucocutaneous candidiasis and hypoparathyroidism may take upto five years and further involvement of adrenal glands may take upto ten years. Thus, a high degree of clinical suspicion is necessary in patients with a single autoimmune endocrine disorder. | * In APS type 1, the time interval between onset of mucocutaneous [[candidiasis]] and [[hypoparathyroidism]] may take upto five years and further involvement of [[adrenal glands]] may take upto ten years. Thus, a high degree of [[clinical]] suspicion is necessary in [[patients]] with a single [[autoimmune]] [[endocrine disorder]]. | ||
*Once a patient has been diagnosed with a single autoimmune disorder. [[Screening (medicine)|Screening]] should be done for presence of other [[Autoantibodies|auto-antibodies]] such as [[21-Hydroxylase|21- hydroxylase]], 17-hydroxylase, [[thyroid peroxidase]], [[parietal cell]], anti-intrinsic factor and [[islet cell]] antibodies. | *Once a patient has been diagnosed with a single [[autoimmune disorder]]. [[Screening (medicine)|Screening]] should be done for presence of other [[Autoantibodies|auto-antibodies]] such as [[21-Hydroxylase|21- hydroxylase]], 17-hydroxylase, [[thyroid peroxidase]], [[parietal cell]], anti-intrinsic factor and [[islet cell]] antibodies. | ||
*Recent research have shown that in APS, [[autoantibodies]] can develop at any age and there is insufficient evidence to suggest optimum interval between testing. For example patients of celiac disease are often asymptomatic and are detected only after screening for [[transglutaminase]] [[autoantibodies]]. Thus, individuals with single autoimmune disorder should be rescreened for [[autoantibodies]] for other autoimmune | *Recent research have shown that in APS, [[autoantibodies]] can develop at any age and there is insufficient evidence to suggest optimum interval between testing. For example patients of celiac disease are often asymptomatic and are detected only after screening for [[transglutaminase]] [[autoantibodies]]. Thus, individuals with single [[autoimmune disorder]] should be rescreened for [[autoantibodies]] for other [[autoimmune]] conditions at appropriate intervals even if their initial [[autoantibody]] tests are negative. | ||
==References== | ==References== | ||
Revision as of 15:04, 3 October 2017
|
Autoimmune polyendocrine syndrome Microchapters |
|
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune polyendocrine syndrome screening On the Web |
|
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome screening |
|
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
|
Risk calculators and risk factors for Autoimmune polyendocrine syndrome screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Screening
Screening is an important aspect in early diagnosis and management of autoimmune polyendocrine syndrome (APS). The onset of APS is often with a single endocrine disorder and the subsequent involvement of other endocrine/non-endocrine organs may take up to years or decades. In patients of APS, high clinical suspicion should be maintained for presence of other autoimmune disorders.
- In APS type 1, the time interval between onset of mucocutaneous candidiasis and hypoparathyroidism may take upto five years and further involvement of adrenal glands may take upto ten years. Thus, a high degree of clinical suspicion is necessary in patients with a single autoimmune endocrine disorder.
- Once a patient has been diagnosed with a single autoimmune disorder. Screening should be done for presence of other auto-antibodies such as 21- hydroxylase, 17-hydroxylase, thyroid peroxidase, parietal cell, anti-intrinsic factor and islet cell antibodies.
- Recent research have shown that in APS, autoantibodies can develop at any age and there is insufficient evidence to suggest optimum interval between testing. For example patients of celiac disease are often asymptomatic and are detected only after screening for transglutaminase autoantibodies. Thus, individuals with single autoimmune disorder should be rescreened for autoantibodies for other autoimmune conditions at appropriate intervals even if their initial autoantibody tests are negative.